Financial Performance - The company's revenue for Q3 2022 was CNY 178,476,491.30, representing a 24.57% increase compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was CNY 12,936,789.86, a slight decrease of 0.65% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 10,750,661.54, which increased by 14.09% compared to the previous year[5]. - Total operating revenue for the third quarter of 2022 was CNY 446,823,862.70, a slight increase of 0.2% compared to CNY 445,950,409.88 in the same period last year[20]. - Net profit for the third quarter was CNY 39,380,724.76, a decrease of 26.8% compared to CNY 53,826,600.73 in the previous year[21]. - Earnings per share (EPS) for the third quarter was CNY 0.35, down from CNY 0.53 in the same quarter last year[22]. Assets and Liabilities - The total assets at the end of Q3 2022 reached CNY 1,700,933,945.13, marking a 40.43% increase from the end of the previous year[5]. - The company's total liabilities increased to CNY 816,415,663.55, up from CNY 382,828,054.54 year-on-year[21]. - Total equity attributable to shareholders reached CNY 831,292,801.39, compared to CNY 807,053,017.36 in the previous year[21]. - Current assets total CNY 978,088,008.47, up from CNY 858,256,693.11 at the start of the year[18]. - The company's total assets as of September 30, 2022, amount to CNY 1,700,933,945.13, an increase from CNY 1,211,243,283.36 at the beginning of the year[18]. Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 162,678.90, a significant decline of 86.74% compared to the previous year[5]. - Cash flow from operating activities totaled CNY 430,847,358.70, an increase from CNY 380,599,617.66 year-on-year[23]. - The net cash flow from operating activities was 162,678.90, a decrease of 86.8% compared to 1,227,234.45 in the previous period[24]. - Cash inflow from financing activities amounted to 588,484,292.91, up from 353,452,670.00, reflecting a 66.5% increase[24]. - The net cash flow from financing activities increased by 120.67% to CNY 392,968,457.22, attributed to increased investment funds and bank loans[13]. Investments and Expenses - The company reported a 128.61% increase in short-term borrowings, totaling CNY 327,858,000.00, primarily due to the funding needs of a newly established R&D center[9]. - The company’s long-term equity investments increased by 232.62% to CNY 48,135,611.11, reflecting increased investments in joint ventures[9]. - Research and development expenses rose to CNY 29,530,625.12, compared to CNY 24,512,055.83 in the previous year, reflecting a focus on innovation[21]. - The company reported a significant increase in interest expenses, which rose to CNY 9,113,287.89 from CNY 5,269,442.07 year-on-year[21]. Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 13,448[15]. - The largest shareholder, Xi Zubin, holds 31.72% of shares, totaling 36,567,000 shares[15]. - The number of shares held by the top ten unrestricted shareholders includes 5,467,200 shares held by Anhui Lichang Investment Center[16]. - The company has a total of 4,270,700 shares held by Zhejiang Huahai Pharmaceutical Co., Ltd.[16].
共同药业(300966) - 2022 Q3 - 季度财报